ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2024

Dec 5, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2024-12-05

Reporting Person: Claiborne Cary J (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-05	Stock Option (Right to Buy)	$1.15	A	350000	Acquired	2034-12-04	Common Stock (350000)	Direct

Footnotes

F1: The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024.